Companion Diagnostics Market

The companion diagnostics market is reported to reach a valuation of USD 6,059.1 million in 2025 to USD 11,682.8 million by 2035. In 2025, monoclonal antibodies hold significant market share of 78.3% in the year 2025. In 2025, breast cancer dominates the companion diagnostics market with a 30.4% share, driven by its high incidence and success of targeted therapies like HER2 inhibitors. Molecular diagnostics leads with a 49.1% share due to its superior precision in identifying genetic mutations that support personalized treatment strategies.